Inhibitor Therapeutics, Inc.
INTI
$0.08
$0.0110.26%
OTC PK
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 1.73M | 1.77M | 1.85M | 1.82M | 1.90M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 3.43M | 3.60M | 3.67M | 3.56M | 3.66M |
| Operating Income | -3.43M | -3.60M | -3.67M | -3.56M | -3.66M |
| Income Before Tax | -3.30M | -3.43M | -3.45M | -3.29M | -3.34M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -3.30 | -3.43 | -3.45 | -3.29 | -3.34 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -3.30M | -3.43M | -3.45M | -3.29M | -3.34M |
| EBIT | -3.43M | -3.60M | -3.67M | -3.56M | -3.66M |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -0.02 | -0.02 | -0.02 | -0.02 | -0.02 |
| Normalized Basic EPS | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 |
| EPS Diluted | -0.02 | -0.02 | -0.02 | -0.02 | -0.02 |
| Normalized Diluted EPS | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 |
| Average Basic Shares Outstanding | 690.04M | 689.79M | 689.54M | 689.29M | 689.05M |
| Average Diluted Shares Outstanding | 690.04M | 689.79M | 689.54M | 689.29M | 689.05M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |